Log in
ASX:TLX

Telix Pharmaceuticals Limited (TLX.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$1.47
MA: A$1.47▼
A$1.47
52-Week Range N/A
Volume746,789 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited has strategic collaboration with RefleXion Medical for the treatment of high-risk cancers. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:TLX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.telixpharma.com
Phone61 4 4914 8448
EmployeesN/A

Debt

Debt-to-Equity Ratio5.72
Current Ratio4.32
Quick Ratio4.10

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.28 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow8.35
Book ValueA$0.21 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive TLX News and Ratings via Email

Sign-up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Telix Pharmaceuticals Limited (TLX.AX) (ASX:TLX) Frequently Asked Questions

Who are some of Telix Pharmaceuticals Limited (TLX.AX)'s key competitors?

Some companies that are related to Telix Pharmaceuticals Limited (TLX.AX) include (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB), Almirall (LBTSF) and Amarantus BioScience (AMBS).
View all competitors.

What other stocks do shareholders of Telix Pharmaceuticals Limited (TLX.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals Limited (TLX.AX) investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

Who are Telix Pharmaceuticals Limited (TLX.AX)'s key executives?

Telix Pharmaceuticals Limited (TLX.AX)'s management team includes the following people:
  • Dr. Christian P. Behrenbruch B.E., M.B.A., Ph.D., BEng(Hons), MBA, DPhil(Oxon), Co-Founder, MD, CEO & Director (Age 45, Pay $408.09k)
  • Mr. Douglas Cubbin FCPA, GAICD, Chief Financial Officer
  • Mr. Gabriel Liberatore B.Sc., M.A.I.C.D., M.B.A., Ph.D., Group Chief Operating Officer
  • Dr. David N. Cade, Chief Bus. Officer & Head of Investor Relations
  • Mr. Christian Davis, VP Sales and Marketing, EMEA
  • Ms. Melanie Farris M.A.I.C.D., ACIS) BComn, (AGIA, GradDip, ACG, Chief Governance & Risk Officer
  • Dr. Shintaro Nishimura B.Sc., Ph.D., Pres of Telix Japan
  • Ms. Odile Jaume M.B.A., M.Sc., Advisor
  • Mr. Bernard Lambert Ph.D., Pres of Telix USA
  • Dr. Rosalind Wilson M.B.A., MBBS, MBA, Global Head of Drug Devel.

What is Telix Pharmaceuticals Limited (TLX.AX)'s stock symbol?

Telix Pharmaceuticals Limited (TLX.AX) trades on the ASX under the ticker symbol "TLX."

How big of a company is Telix Pharmaceuticals Limited (TLX.AX)?

Telix Pharmaceuticals Limited (TLX.AX) has a market capitalization of $0.00 and generates $3.28 million in revenue each year.

What is Telix Pharmaceuticals Limited (TLX.AX)'s official website?

The official website for Telix Pharmaceuticals Limited (TLX.AX) is www.telixpharma.com.

How can I contact Telix Pharmaceuticals Limited (TLX.AX)?

The company can be reached via phone at 61 4 4914 8448.

This page was last updated on 10/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.